The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Open accessAbstract
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The IFN-I response could also expose the tumor cells to surveillance by the immune system96, 97.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“multiple studies have shown that DNA demethylating agents among other epigenetic modulators can induce a type I IFN response in cancer cells through the de-repression of endogenous retroviruses (ERVs) and activation of the MDA5-MAVS pathway38–40.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“DAC treatment could induce expression of retrotransposons normally silenced by DNA methylation, which could also augment tumor immunogenicity10–14,99.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“inactivated typical enhancers were associated with collagen fibril organization and chemotaxis GO terms and were enriched for binding motifs of immune-related TFs, including STAT1 (Fig. 2a, b)12,13.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“inhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immunogenicity and the function of infiltrating T-cells, NK-cells and macrophages 196 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [196]
In the citing paper
“derepression of endogenous retroviral elements coupled to robust type I and type III IFN signaling”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chiappinelli et al., 2015
In the citing paper
“Certainly, this dual epigenetic targeting may influence additional antiproliferative mechanisms and further enhance antitumor surveillance by the immune system (Chiappinelli et al., 2015).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Chiappinelli et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
Cited by
Sorted by citations
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520
The molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Self-citationTumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401
Self-citationThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Self-citationThe immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
RIG-I-like receptors: their regulation and roles in RNA sensing
Rehwinkel, J., & Gack, M. U. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0288-3 · Cited by 1,770
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0215-7 · Cited by 1,672
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,570
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A. K., & Ribas, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,525
Ten things you should know about transposable elements
Bourque, G., Burns, K. H., Gehring, M., Gorbunova, V., Seluanov, A., Hammell, M., Imbeault, M., Izsvák, Z., Levin, H. L., Macfarlan, T. S., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1577-z · Cited by 1,430
Regulatory activities of transposable elements: from conflicts to benefits
Chuong, E. B., Elde, N. C., & Feschotte, C. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.139 · Cited by 1,489
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J. J., & Baylin, S. B. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,153
Self-citationCold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau‐Guilemond, J., Valsesia‐Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,140
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Hong, D. S., Kang, Y., Borad, M. J., Sachdev, J. C., Ejadi, S., Lim, H. Y., Brenner, A. J., Park, K., Lee, J., Kim, T., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0802-1 · Cited by 1,026
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P. J., Cameron, S. B., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C. A., Petruzzelli, L., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.17 · Cited by 968
Beg, M. S., Brenner, A. J., Sachdev, J. C., Borad, M. J., Kang, Y., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 931
Breast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 898
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G. A. M., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 808
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Sheng, W., LaFleur, M. W., Nguyen, T. H., Chen, S., Chakravarthy, A., Conway, J. R., Li, Y., Chen, H., Yang, H., Hsu, P.-H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.052 · Cited by 693
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K., Panda, A., Iracheta-Vellve, A., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J., et al. (2019) · Nature · doi:10.1038/s41586-018-0768-9 · Cited by 697
The cGAS–STING pathway and cancer
Samson, N., & Ablasser, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00468-w · Cited by 740
Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A. J., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 671
Targeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 665
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A.-T., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 630
Self-citationCancer stemness, intratumoral heterogeneity, and immune response across cancers
Miranda, A., Hamilton, P. T., Zhang, A. W., Pattnaik, S., Becht, É., Mezheyeuski, A., Bruun, J., Micke, P., de Reyniès, A., & Nelson, B. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818210116 · Cited by 581
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 587
Transposable elements in cancer
Burns, K. H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.35 · Cited by 572
Epigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & Carvalho, D. D. D. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 559
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Glioma epigenetics: From subclassification to novel treatment options
Gusyatiner, O., & Hegi, M. E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.010 · Cited by 556
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
Self-citationDNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Jung, H., Kim, H. S., Kim, J. Y., Sun, J., Ahn, J. S., Ahn, M., Park, K., Esteller, M., Lee, S., & Choi, J. K. (2019) · Nature Communications · doi:10.1038/s41467-019-12159-9 · Cited by 547
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
Self-citationRegulation of transposable elements by DNA modifications
Deniz, Ö., Frost, J. M., & Branco, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0106-6 · Cited by 500
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
The role of retrotransposable elements in ageing and age-associated diseases
Gorbunova, V., Seluanov, A., Mita, P., McKerrow, W., Fenyö, D., Boeke, J. D., Linker, S. B., Gage, F. H., Kreiling, J. A., Petrashen, A. P., et al. (2021) · Nature · doi:10.1038/s41586-021-03542-y · Cited by 446
Integrated Molecular Characterization of Testicular Germ Cell Tumors
Shen, H., Shih, J., Hollern, D. P., Wang, L., Bowlby, R., Tickoo, S. K., Thórsson, V., Mungall, A. J. J., Newton, Y., Hegde, A. M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.039 · Cited by 456
Nabet, B. Y., Qiu, Y., Shabason, J. E., Wu, T. J., Yoon, T., Kim, B. C., Benci, J. L., DeMichele, A. M., Tchou, J. C., Marcotrigiano, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.031 · Cited by 456
Roles of transposable elements in the regulation of mammalian transcription
Fueyo, R., Judd, J., Feschotte, C., & Wysocka, J. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00457-y · Cited by 451
Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation
Ahmad, S., Mu, X., Yang, F., Greenwald, E., Park, J. W., Jacob, E., Zhang, C.-Z., & Hur, S. (2018) · Cell · doi:10.1016/j.cell.2017.12.016 · Cited by 449
Cellular origins of dsRNA, their recognition and consequences
Chen, Y. G., & Hur, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00430-1 · Cited by 457
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
Moroishi, T., Hayashi, T., Pan, W., Fujita, Y., Holt, M. V., Qin, J., Carson, D. A., & Guan, K. (2016) · Cell · doi:10.1016/j.cell.2016.11.005 · Cited by 441
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Self-citationRegulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors
Onomoto, K., Onoguchi, K., & Yoneyama, M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00602-7 · Cited by 440
Interferons α and β in cancer: therapeutic opportunities from new insights
Borden, E. C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0011-2 · Cited by 428
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 427
Double-Stranded RNA Sensors and Modulators in Innate Immunity
Hur, S. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041356 · Cited by 420
Immune checkpoint therapy in liver cancer
Xu, F., Jin, T., Zhu, Y., & Dai, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0777-4 · Cited by 401
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W. T., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 412
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Zappasodi, R., Serganova, I. S., Cohen, I., Maeda, M., Shindo, M., Şenbabaoğlu, Y., Watson, M. J., Leftin, A., Maniyar, R. R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 401
Self-citationResurrection of endogenous retroviruses during aging reinforces senescence
Liu, X., Liu, Z., Wu, Z., Ren, J., Fan, Y., Sun, L., Cao, G., Niu, Y., Zhang, B., Ji, Q., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.017 · Cited by 390
Measuring and interpreting transposable element expression
Lanciano, S., & Cristofari, G. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0251-y · Cited by 415
DNA damage and repair in age-related inflammation
Zhao, Y., Simon, M. A., Seluanov, A., & Gorbunova, V. A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00751-y · Cited by 400
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 377
Self-citationTransposable elements in human genetic disease
Payer, L. M., & Burns, K. H. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0165-8 · Cited by 366
Alternative tumour-specific antigens
Smith, C. C., Selitsky, S. R., Chai, S., Armistead, P. M., Vincent, B. G., & Serody, J. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0162-4 · Cited by 366
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
Liu, H., Golji, J., Brodeur, L. K., Chung, F. S., Chen, J. T., deBeaumont, R. S., Bullock, C., Jones, M. D., Kerr, G., Li, L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0302-5 · Cited by 359
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Cao, J. P., & Yan, Q. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.003 · Cited by 355
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature · doi:10.1038/nature20132 · Cited by 348
Platzbecker, U., Middeke, J. M., Sockel, K., Herbst, R., Wolf, D. G. F., Baldus, C. D., Oelschlägel, U., Mütherig, A., Fransecky, L. R., Noppeney, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30580-1 · Cited by 347
Human Endogenous Retroviruses Are Ancient Acquired Elements Still Shaping Innate Immune Responses
Grandi, N., & Tramontano, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02039 · Cited by 354
Immune escape and immunotherapy of acute myeloid leukemia
Vago, L., & Gojo, I. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129204 · Cited by 356
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats
Brocks, D., Schmidt, C. R., Daskalakis, M., Jang, H. S., Shah, N. M., Li, D., Li, J., Zhang, B., Hou, Y., Laudato, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3889 · Cited by 339
Regulation of cGAS- and RLR-mediated immunity to nucleic acids
Ablasser, A., & Hur, S. (2019) · Nature Immunology · doi:10.1038/s41590-019-0556-1 · Cited by 339
Development of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 352
Epigenetic drivers of tumourigenesis and cancer metastasis
Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.004 · Cited by 340
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 337
Epigenetic therapy for ovarian cancer: promise and progress
Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 319
Self-citationEnnishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1090 · Cited by 318
A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation
Dias, A. G., Sampaio, N. G., & Rehwinkel, J. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.08.007 · Cited by 309
Gut stem cell necroptosis by genome instability triggers bowel inflammation
Wang, R., Li, H., Wu, J., Cai, Z., Li, B., Ni, H., Qiu, X., Chen, H., Liu, W., Yang, Z., et al. (2020) · Nature · doi:10.1038/s41586-020-2127-x · Cited by 314
Self-citationTumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 324
Combining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 313
Self-citationEndogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
Smith, C. C., Beckermann, K. E., Bortone, D. S., De Cubas, A. A., Bixby, L. M., Lee, S. J., Panda, A., Ganesan, S., Bhanot, G., Wallen, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121476 · Cited by 303
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J., Pasero, P., & Postel-Vinay, S. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 306
Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency
Mehdipour, P., Marhon, S. A., Ettayebi, I., Chakravarthy, A., Hosseini, A., Wang, Y., de Castro, F. A., Loo Yau, H., Ishak, C., Abelson, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2844-1 · Cited by 304
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine
Yu, X., Zhao, H., Wang, R., Chen, Y., Ouyang, X., Li, W., Sun, Y., & Peng, A. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01803-z · Cited by 311
Parikh, A. R., Szabolcs, A., Allen, J. N., Clark, J. W., Wo, J. Y.-L., Raabe, M. J., Thel, H. L., Hoyos, D., Mehta, A., Arshad, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00269-7 · Cited by 301
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M. K., Shih, I., Wang, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712514114 · Cited by 297
Self-citationPappalardi, M. B., Keenan, K., Cockerill, M. J., Kellner, W. A., Stowell, A. I. J., Sherk, C. S., Wong, K., Pathuri, S., Briand, J., Steidel, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00249-x · Cited by 290
Self-citationMarked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285
Kong, Y., Rose, C. M., Cass, A. A., Williams, A. G., Darwish, M., Lianoglou, S., Haverty, P. M., Tong, A.-J., Blanchette, C., Albert, M. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13035-2 · Cited by 285
Guler, G. D., Tindell, C. A., Pitti, R., Wilson, C., Nichols, K., KaiWai Cheung, T., Kim, H.-J., Wongchenko, M., Yan, Y., Haley, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.002 · Cited by 277
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275
Self-citationKDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
Zhang, S.-M., Cai, W. L., Liu, X., Thakral, D., Luo, J., Chan, L. H., McGeary, M. K., Song, E., Blenman, K. R. M., Micevic, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03994-2 · Cited by 272
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 270
The Role of DNA Methylation in Cancer
Lakshminarasimhan, R., & Liang, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43624-1_7 · Cited by 281
Immune responses to endogenous retroelements: taking the bad with the good
Kassiotis, G., & Stoye, J. P. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.27 · Cited by 270
DNA methylation in mammalian development and disease
Smith, Z. D., Hetzel, S., & Meissner, A. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00760-8 · Cited by 310
Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., Qiu, X., Cañadas, I., Roehle, K., Heckler, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00185-w · Cited by 258
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
Hu, M., Zhou, M., Bao, X., Pan, D., Jiao, M., Liu, X., Li, F., & Li, C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139333 · Cited by 260
Lysine catabolism reprograms tumour immunity through histone crotonylation
Yuan, H., Wu, X., Wu, Q., Chatoff, A. G., Megill, E., Gao, J., Huang, T., Duan, T., Yang, K., Jin, C., et al. (2023) · Nature · doi:10.1038/s41586-023-06061-0 · Cited by 250
Metadata
- Authors
- Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., Makarov, V., Buhu, S., Slamon, D. J., Wolchok, J. D., Pardoll, D. M., Beckmann, M. W., Zahnow, C. A., Merghoub, T., Chan, T. A., Baylin, S. B., & Strick, R.
- Affiliations
- Johns Hopkins University (US)
- Universitätsklinikum Erlangen (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Case Western Reserve University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Baylin, Stephen B.
- Strick, Reiner
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 162
- Issue
- 5
- Pages
- 974-986
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4556003
- OpenAlex
- W1953890763
- Cited by
- 2,022
- References
- 94
- Citations by year
- 2026: 193 · 2025: 188 · 2024: 211 · 2023: 209 · 2022: 225 · 2021: 250 · 2020: 184 · 2019: 163 · 2018: 161 · 2017: 133 · 2016: 93 · 2015: 10
- FWCI
- 65.10
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA058184, CA058184, F32CA183214, P30CA008748)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- hypomethylating agents, DNA methylation, type I interferon response, double-stranded RNA sensing, endogenous retroviruses, ovarian cancer, melanoma, TLR3, MAVS, interferon-beta, apoptosis, immune checkpoint therapy, CTLA-4, tumor immune microenvironment, epigenetic reprogramming
- MeSH terms
- Animals, Azacitidine, Female, Humans, Immunotherapy, Interferon Type I, Lung Neoplasms, Melanoma, Mice, Inbred C57BL, Ovarian Neoplasms, RNA, Double-Stranded, DNA Modification Methylases, DNA Methylation, Endogenous Retroviruses, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
